Boltz key facts
as of Oct 2026- Operator of an AI-based biotechnology company designed to accelerate drug discovery from hit identification to lead optimization.
- Boltz is valued at approximately $130.0M as of Oct 2026 (last reported valuation).
- It has raised $28.0M; the latest was Seed Round ($28.0M) in Jan 2026.
- Notable investors include Andreessen Horowitz, Amplify Partners, Obvious Ventures, Clément Delangue, Factorial Capital — 6 tracked in total.
- Status: Privately Held (backing).
Boltz's last reported valuation, Jan 2026. Nothing priced has surfaced since.
- ·Watch Boltz: the Monday email on marks, rounds and moves
Boltz funding rounds
No funding rounds for Boltz are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Boltz valuation
Boltz's last reported valuation was $130 million in Jan 2026. No priced round, secondary trade or fund mark has surfaced since.
Boltz investors
6 investors are on record for Boltz, including Andreessen Horowitz, Amplify Partners, Obvious Ventures and Clément Delangue.
About Boltz
Operator of an AI-based biotechnology company designed to accelerate drug discovery from hit identification to lead optimization. The company's platform defines and refines the biological targets with AI assistance, runs large-scale screening across distributed infrastructure, and integrates experimental data to continuously improve results, enabling users to get AI-powered drug discovery platform and simplify their operation.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2024
- Employees
- 15
- Website
- boltz.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.